Related Experiment Video

Updated: Oct 25, 2025

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates
14:32

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates

Published on: February 27, 2016

8.4K

SIRT1: a promising therapeutic target in type 2 diabetes mellitus

Ainaz Mihanfar1, Maryam Akbarzadeh2, Saber Ghazizadeh Darband3

  • 1Department of Biochemistry, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran.

Archives of Physiology and Biochemistry
|August 11, 2021
PubMed

Insights

Targeting Sirtuin 1 (SIRT1) shows promise for treating type 2 diabetes mellitus (T2DM). Activating SIRT1 may reverse T2DM complications by improving metabolism and protecting pancreatic cells.

Area of Science:

  • Metabolic research
  • Endocrinology
  • Molecular biology

Background:

  • Rising global type 2 diabetes mellitus (T2DM) rates necessitate novel therapeutic approaches.
  • Sirtuin 1 (SIRT1), an NAD+-dependent deacetylase, regulates key metabolic and cellular processes implicated in T2DM.

Approach:

  • This review synthesizes current knowledge on SIRT1's physiological roles.
  • It examines SIRT1's involvement in T2DM pathogenesis.
  • The therapeutic potential of targeting SIRT1 for T2DM treatment is evaluated.

Key Points:

  • SIRT1 influences glucose/lipid metabolism, insulin resistance, inflammation, oxidative stress, and mitochondrial function.
  • SIRT1 plays a role in insulin secretion and pancreatic beta-cell protection.
  • SIRT1 activators demonstrate potential in mitigating T2DM-related organ damage.

Conclusions:

  • SIRT1 is a critical regulator of metabolic homeostasis and cellular protection.
  • Targeting SIRT1 represents a promising therapeutic strategy for managing T2DM and its associated complications.
Keywords:
SIRT1T2DMcardiomyopathynephropathyneuropathyretinopathy

More Related Videos

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

6.0K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

906

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
493
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
589
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
360
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.9K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.4K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.5K